RxDoctor Payments DataLook up a doctor →

Lawrence Green, MD

Procedural Dermatology · Rockville, MDNPI 1073581344

Payments from drug & device makers

$3,010,833in general payments, 2019–2025

Across 1,932 payments — averaging $1558.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$678K
  • Janssen Research & Development, LLC$321K
  • Amgen$316K
  • Incyte Corporation$235K
  • Pfizer$174K
  • Dermavant Sciences, Inc.$136K
  • plus $1.2M from 37 others
$883,458in research payments, 2019–2025

Across 49 payments — averaging $18,030 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$464K
  • Bristol Myers Squibb$302K
  • E.r. Squibb & Sons, L.L.C.$57K
  • Eli Lilly$33K
  • Arcutis Biotherapeutics, Inc.$20K
  • Novartis$7K

What the payments were for

  • Consulting fees$169,69316%
  • Speaking & faculty fees$775,22172%
  • Travel & lodging$90,6438%
  • Food & beverage$39,5534%
  • Education$730%
  • Gifts$1170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few procedural dermatology providers in Marylandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$99,905
Medicare patients
354
Services billed
1,083

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clindamycin Phosphate13$2,208
Gentamicin Sulfate12$394
Triamcinolone Acetonide32$134

Paid to pharmacies, not to this prescriber.

Other procedural dermatology in Rockville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →